Selective CDK2 Spirotriazine Inhibitors for Resistant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for abnormal cellular proliferation, including cancers and tumors, face challenges with resistance to current CDK4/6 inhibitors, particularly in Rb-negative or Rb-positive cancers, and the need for compounds with high oral bioavailability and metabolic stability.
Innovation Solution
Development of substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones that act as selective inhibitors of CDK2, CDK4, and/or CDK6, offering additional cell-cycle inhibition mechanisms, especially in resistant cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK4/6 inhibitors are used to treat abnormal cellular proliferation, then cancer treatment efficacy is improved, but resistance develops in Rb-negative or Rb-positive cancers
Solution Approach 1:
The patent divides the CDK inhibition function into separate targets: CDK4/6 inhibition for Rb-positive cancers and CDK2 inhibition for Rb-negative or resistant cancers. This segmentation allows each compound to address specific resistance mechanisms without requiring a single pan-resistant solution.
Solution Approach 2:
The patent modifies the molecular structure of pyrimidine-based compounds to change their selectivity parameters. By adjusting structural parameters (R1-R8 substituents), the compounds can be optimized for high CDK2 selectivity in resistant cancers while maintaining CDK4/6 activity in sensitive cancers.
2Reliability
If new pyrimidine-based CDK inhibitors are developed to overcome resistance, then treatment effectiveness is improved, but oral bioavailability and metabolic stability must be maintained
Solution Approach 1:
The patent systematically optimizes molecular parameters (R1-R8) to balance pharmacological activity with pharmacokinetic properties. Specific parameter ranges are established to ensure high oral bioavailability and metabolic stability while maintaining CDK inhibition effectiveness.
Solution Approach 2:
The patent creates composite molecular structures combining pyrimidine core with specific side chains (R1-R8) that provide both CDK inhibition activity and favorable pharmacokinetic properties. These composite structures achieve multiple objectives simultaneously.
3Reliability
If selective CDK2 inhibition is used in Rb-negative cancers, then cell-cycle inhibition is improved, but CDK4/6 inhibition may be compromised
Solution Approach 1:
The patent applies local quality by making different regions of the molecule (different R1-R8 positions) responsible for different binding interactions: some regions target CDK2 specifically while other regions maintain CDK4/6 binding capability. This allows selective inhibition where needed without complete loss of CDK4/6 activity.
Solution Approach 2:
The patent creates dynamic inhibition profiles where the compound can adapt its binding preference based on the cancer type. Through structural dynamics and binding conformation changes, the compound can prioritize CDK2 inhibition in Rb-negative cancers while maintaining CDK4/6 inhibition in Rb-positive cancers.
Data Source
AI summary
This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions. The inhibitors are pyrimidine-based N-heterocyclic compounds of formula: